Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Again Rejects Xarelto, This Time In DVT Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. cost watchdog NICE asks for further data on use of Bayer's Xarelto for the treatment and prevention of deep vein thrombosis, having made similar demands at the start of the year on its use in atrial fibrillation.

You may also be interested in...



European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

NICE Clears Pradaxa For Stroke Prevention, Rejects Appeal By NHS Budget Holders

Following a failed appeal by regional NHS payers worried about its cost, Boehringer Ingelheim's Pradaxa is finally recommended by the U.K.'s cost watchdog, NICE, for preventing stroke associated with atrial fibrillation.

Bayer Chief Worried About Innovation, Spanish Debts

Bayer's chairman, Marijn Dekkers, calls for a greater appreciation of pharmaceutical inventors and brands, as the diversified Big Pharma reported group sales up 4% in 2011, and profits up 90% on lower charges.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel